The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Fasting Glucose to Insulin Ratio Is a Useful Measure of Insulin Sensitivity in Women with Polycystic Ovary Syndrome1
Abstract
Women with polycystic ovary syndrome (PCOS) are profoundly insulin resistant, and the resultant hyperinsulinemia exacerbates the reproductive abnormalities of the syndrome. Agents that ameliorate insulin resistance and reduce circulating insulin levels could provide a new therapeutic modality for PCOS. Identifying the subset of PCOS women who are most insulin resistant may therefore be useful for selecting women who will respond to this therapy. We examined the correlation of basal and oral glucose-stimulated glucose and insulin levels and fasting and stimulated glucose/insulin (G:I) ratios with parameters of insulin sensitivity obtained by frequently sampled i.v. glucose tolerance test (FSIGT) to assess whether there is a simple screening test for insulin resistance in PCOS. Forty PCOS women (aged 18-40 yr; body mass index, >26 kg/m2) and 15 control women matched for age, weight, and ethnicity underwent both a 75-g oral glucose tolerance test (OGTT) and a FSIGT. The insulin sensitivity index (S(I)) was calculated by application of the minimal model of glucose kinetics to the dynamics of plasma glucose and insulin levels during the FSIGT. The best correlation in PCOS between S(I) and a fasting level was found with fasting G:I ratios (r = 0.73; P < 0.0001). A less substantial, but significant, correlation was found with fasting insulin levels (r = 0.50; P < 0.001), and no significant correlation was found with fasting glucose levels (r = 0.24; P = NS). The fasting G:I was more strongly correlated with S(I) than with integrated glucose and insulin responses during the OGTT. The only stronger correlation was with the OGTT 2 h G:I ratio (r = 0.74; P < 0.001). Stepwise regression analysis with S(I) as the dependent variable and fasting glucose and insulin levels, area under the curve for glucose and insulin, and a fasting G:I ratio showed that only the fasting G:I ratio was significantly predictive of S(I) in the model (F to remove value = 38.1; P < 0.001). When viewed as a screening test for insulin resistance in PCOS, setting a value of the fasting G:I ratio of less than 4.5 as abnormal (using an S(I) value below the 10th percentile of our control population as evidence for insulin resistance), the sensitivity of a fasting G:I ratio was 95%, the specificity was 84%, the positive predictive value was 87%, and the negative predictive value was 94%. Receiver operator curve analysis showed that this fasting G:I ratio was the single best screening measure for detecting insulin resistance. We conclude that a fasting G:I ratio may be useful as a screening test for insulin resistance in obese non-Hispanic white PCOS women. This may be a clinically useful parameter for selecting PCOS women most likely to respond to therapeutic interventions that improve insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Self-citationProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Self-citationBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease*
BURGHEN, G. A., GIVENS, J. R., & KITABCHI, A. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-113 · Cited by 919
Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
How good a marker is insulin level for insulin resistance?
Laakso, M. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116768 · Cited by 726
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
DUNAIF, A., GRAF, M., MANDELI, J., LAUMAS, V., & DOBRJANSKY, A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-499 · Cited by 586
Self-citationEvidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Shelley, D. R., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 546
Self-citationDunaif, A., Scott, D., Finegood, D., Quintana, B., & Whitcomb, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 524
Self-citationTai, M. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.2.152 · Cited by 498
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Dunaif, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.942 · Cited by 450
Self-citationSaad, M. F., Anderson, R. L., Laws, A., Watanabe, R. M., Kades, W. W., Chen, Y. D. I., Sands, R. E., Pei, D., Savage, P. J., & Bergman, R. N. (1994) · Diabetes · doi:10.2337/diab.43.9.1114 · Cited by 376
Insulin Action and Age: European Group for the Study of Insulin Resistance (EGIR)
Ferrannini, E., Vichi, S., Beck-Nielsen, H., Laakso, M., Paolisso, L., Smith, G., & European Group for the Study of Insulin Resistance (1996) · Diabetes · doi:10.2337/diab.45.7.947 · Cited by 343
NESTLER, J. E., BARLASCINI, C. O., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., CLORE, J. N., & BLACKARD, W. G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1027 · Cited by 338 · cited 1×
“The short term use of agents that lower insulin secretion, such as diazoxide or somatostatin, produces similar effects (20, 21).”
BackgroundMenstrual Cyclicity After Metformin Therapy in Polycystic Ovary Syndrome
M, E., ACOSTA, A., & MENDOZA, S. (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00296-2 · Cited by 311
Dunaif, A. E., Sorbara, L. R., Delson, R., & Green, G. (1993) · Diabetes · doi:10.2337/diab.42.10.1462 · Cited by 131
Self-citationNorman, R. J., Mahabeer, S., & Masters, S. C. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57297-5 · Cited by 115
Prelević, G. M., Würzburger, M. I., Balint‐Peric, L., & Nešić, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)92270-r · Cited by 109
Modan, M., Harris, M. I., & Halkin, H. (1989) · Diabetes · doi:10.2337/diab.38.12.1630 · Cited by 86
Insulin Resistance and Ovarian Hyperandrogenism
Dunaif, A. E. (1992) · The Endocrinologist · doi:10.1097/00019616-199207000-00007 · Cited by 52
Self-citationNestler, J. E., & Jakubowicz, D. J. (1997) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199702000-00017 · Cited by 52
Evaluation of WHO and NDDG criteria for impaired glucose tolerance
Motala, A. A., & Omar, M. A. (1994) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(94)90017-5 · Cited by 33
Efficacy of troglitazone measured by insulin resistance index
Nagasaka, S., Iwamoto, Y., Ishikawa, S., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62350-1 · Cited by 24
Parra, A., Ramírez, A., & Monteros, A. E. D. L. (1995) · PubMed · Cited by 17
Cited by
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Self-citationAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Self-citationDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Self-citationEhrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Metadata
- Authors
- Legro, R. S., Finegood, D., & Dunaif, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-08
- Volume
- 83
- Issue
- 8
- Pages
- 2694-2698
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2152138526
- Cited by
- 673
- References
- 30
- FWCI
- 22.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.